Phathom Pharmaceuticals (PHAT)
(Delayed Data from NSDQ)
$9.18 USD
+0.08 (0.88%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $9.19 +0.01 (0.11%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Balance Sheet
Fiscal Year End for Phathom Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 381 | 155 | 183 | 288 | 244 |
Receivables | 2 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 1 | 0 | 0 | 0 | 0 |
Other Current Assets | 13 | 5 | 3 | 4 | 12 |
Total Current Assets | 397 | 161 | 187 | 291 | 256 |
Net Property & Equipment | 2 | 1 | 1 | 1 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 8 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 5 | 1 | 0 | 0 | 0 |
Total Assets | 414 | 165 | 189 | 295 | 257 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 13 | 10 | 5 | 17 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 7 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 18 | 16 | 13 | 31 | 2 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 7 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 39 | 26 | 19 | 56 | 4 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 138 | 95 | 90 | 40 | 23 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 310 | 117 | 8 | 4 | 2 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 487 | 240 | 117 | 101 | 29 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 856 | 652 | 602 | 580 | 484 |
Retained Earnings | -929 | -727 | -529 | -385 | -256 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -73 | -75 | 72 | 194 | 228 |
Total Liabilities & Shareholder's Equity | 414 | 165 | 189 | 295 | 257 |
Total Common Equity | -73 | -75 | 72 | 194 | 228 |
Shares Outstanding | 57.20 | 41.60 | 30.50 | 28.90 | 24.50 |
Book Value Per Share | -1.27 | -1.80 | 2.37 | 6.72 | 9.30 |
Fiscal Year End for Phathom Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 381 | 214 | 249 | 130 |
Receivables | NA | 2 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 1 | 0 | 0 | 0 |
Other Current Assets | NA | 13 | 13 | 9 | 10 |
Total Current Assets | NA | 397 | 227 | 258 | 140 |
Net Property & Equipment | NA | 2 | 2 | 1 | 1 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 8 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 5 | 7 | 4 | 1 |
Total Assets | NA | 414 | 237 | 265 | 144 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 13 | 6 | 4 | 5 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 18 | 15 | 16 | 9 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 7 | 2 | 0 | 0 |
Total Current Liabilities | NA | 39 | 24 | 22 | 14 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 138 | 99 | 98 | 97 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 131 | 127 | 122 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 487 | 255 | 247 | 234 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 856 | 831 | 823 | 675 |
Retained Earnings | NA | -929 | -849 | -806 | -765 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | -73 | -18 | 18 | -90 |
Total Liabilities & Shareholder's Equity | NA | 414 | 237 | 265 | 144 |
Total Common Equity | 0 | -73 | -18 | 18 | -90 |
Shares Outstanding | 58.40 | 57.20 | 56.80 | 56.60 | 43.60 |
Book Value Per Share | 0.00 | -1.27 | -0.31 | 0.31 | -2.07 |